EGFR and neoplasm: A systemic review and meta-analysis of 32 studies with 4527 advanced NSCLC patients reported a pooled sensitivity and specificity of 0.70 and 0.98 respectively for ctDNA EGFR mutation status in plasma samples compared to tumor tissues [97].